KRKenneth M. Rassnick

Kenneth M. Rassnick

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kenneth M. Rassnick has a total of 13 co-authors. Here are the top co-authors by number of shared publications:

  • Amy Bengtson

    Harrington Oncology Program, Tufts University School of Veterinary Medicine, North Grafton, MA., Tufts University School of Veterinary Medicine, North Grafton, MA

    1 shared publication
  • Antony S. Moore

    Harrington Oncology Program, Tufts University School of Veterinary Medicine, North Grafton, MA., Tufts University School of Veterinary Medicine, North Grafton, MA

    1 shared publication
  • David L. Hutto

    Section of Pathology, Tufts University School of Veterinary Medicine, North Grafton, MA

    1 shared publication
  • David M. Ruslander

    Harrington Oncology Program, Tufts University School of Veterinary Medicine, North Grafton, MA., Tufts University School of Veterinary Medicine, North Grafton, MA

    1 shared publication
  • Helen T. Power

    Dermatology for Animals, Campbell, CA

    1 shared publication
  • Jeffrey L. Johnson

    Duke Comprehensive Cancer Center, Duke University Medical Center, Durham, NC

    1 shared publication

Latest Publications

  • Open Access

    CCNU in the Treatment of Canine Epitheliotropic Lymphoma

    by Laurel E. Williams, Kenneth M. Rassnick, Helen T. Power, Susan E. Lana, Kirsten E Morrison-Collister, K. Hansen, Jeffrey L. Johnson


  • Retrospective Study of Orthovoltage Radiation Therapy for Nasal Tumors in 42 Dogs

    by Nicole C. Northrup, Sheila M. Etue, David M. Ruslander, Kenneth M. Rassnick, David L. Hutto, Amy Bengtson, William Rand, Antony S. Moore

    Megavoltage radiation therapy currently is the standard of care for dogs with nasal tumors. Some studies report that surgery and adjunctive orthovoltage radiation therapy result in longer control of these tumors than does megavoltage radiation therapy alone. This study reports less effective control of nasal tumors in dogs treated with surgery and orthovoltage radiation than previously observed, supporting the superiority of megavoltage radiation therapy for these tumors. In addition, this study suggests 2 new prognostic indicators for dogs with nasal tumors and describes toxicity associated with surgery and orthovoltage therapy. Forty-two dogs with nasal tumors were treated with surgical cytoreduction and 48 Gy orthovoltage radiation therapy administered in twelve 4-Gy fractions. Median survival was 7.4 months. One- and 2-year survival rates were 37% and 17%, respectively. Dogs with facial deformity had shorter survival than those without deformity (P = .005). Dogs with resolution of clinical signs after treatment had longer survival than those with chronic nasal signs (P = .0001). Acute radiation toxicity was moderate to severe for skin and eye and negligible for oral mucosa. Toxicity healed within 1 month after radiation therapy. Late toxicity was mild, but 70% of evaluable dogs experienced persistent ocular signs. Only 39% of dogs achieved a disease-free period.